Steris plc (STE) | Financial Analysis & Statements
Steris plc Large-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
1.5B
Gross Profit
655.5M
43.81%
Operating Income
273.7M
18.29%
Net Income
194.3M
12.99%
EPS (Diluted)
$1.96
Balance Sheet Metrics
Total Assets
10.6B
Total Liabilities
3.4B
Shareholders Equity
7.2B
Debt to Equity
0.48
Cash Flow Metrics
Operating Cash Flow
269.4M
Free Cash Flow
199.5M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Steris plc Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 5.5B | 5.1B | 4.5B | 4.2B | 3.1B |
| Cost of Goods Sold | 3.1B | 2.9B | 2.6B | 2.3B | 1.8B |
| Gross Profit | 2.4B | 2.2B | 2.0B | 1.9B | 1.3B |
| Gross Margin % | 44.0% | 43.2% | 43.7% | 44.6% | 43.2% |
| Operating Expenses | |||||
| Research & Development | 107.6M | 103.7M | 98.5M | 86.7M | 66.3M |
| Selling, General & Administrative | 1.3B | 1.3B | 1.1B | 1.3B | 731.3M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 1.4B | 1.4B | 1.2B | 1.4B | 797.6M |
| Operating Income | 960.8M | 862.2M | 791.6M | 477.9M | 545.5M |
| Operating Margin % | 17.6% | 16.8% | 17.5% | 11.3% | 17.6% |
| Non-Operating Items | |||||
| Interest Income | 8.4M | 11.0M | - | 6.3M | 6.3M |
| Interest Expense | 86.3M | 144.4M | 110.8M | 89.5M | 37.2M |
| Other Non-Operating Income | -86.8M | -26.0M | -485.0K | -27.9M | 2.9M |
| Pre-tax Income | 796.2M | 702.8M | 680.3M | 366.8M | 517.5M |
| Income Tax | 184.6M | 149.5M | 124.1M | 82.3M | 120.7M |
| Effective Tax Rate % | 23.2% | 21.3% | 18.2% | 22.4% | 23.3% |
| Net Income | 616.1M | 380.1M | 105.8M | 242.9M | 396.9M |
| Net Margin % | 11.3% | 7.4% | 2.3% | 5.8% | 12.8% |
| Key Metrics | |||||
| EBITDA | 1.4B | 1.4B | 1.3B | 1.0B | 771.0M |
| EPS (Basic) | $6.24 | $3.83 | $1.07 | $2.50 | $4.66 |
| EPS (Diluted) | $6.20 | $3.81 | $1.07 | $2.48 | $4.63 |
| Basic Shares Outstanding | 98575000 | 98787000 | 99706000 | 97535000 | 85203000 |
| Diluted Shares Outstanding | 98575000 | 98787000 | 99706000 | 97535000 | 85203000 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Steris plc Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 171.7M | 207.0M | 208.4M | 348.3M | 220.5M |
| Short-term Investments | - | - | - | - | - |
| Accounts Receivable | 1.0B | 1.0B | 865.0M | 799.0M | 609.4M |
| Inventory | 581.3M | 674.5M | 604.4M | 575.0M | 315.1M |
| Other Current Assets | 203.8M | 174.3M | 176.1M | 156.6M | 66.8M |
| Total Current Assets | 2.0B | 2.9B | 2.0B | 1.9B | 1.2B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 1.2B | 1.1B | 1.0B | 1.0B | 909.0M |
| Goodwill | 10.0B | 10.3B | 9.8B | 12.1B | 7.0B |
| Intangible Assets | 1.9B | 2.1B | 2.1B | 3.3B | 898.4M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 83.0M | 66.2M | 1.1B | 70.7M | 52.7M |
| Total Non-Current Assets | 8.1B | 8.2B | 8.8B | 9.5B | 5.4B |
| Total Assets | 10.1B | 11.1B | 10.8B | 11.4B | 6.6B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 280.8M | 251.7M | 264.2M | 225.7M | 157.0M |
| Short-term Debt | 159.2M | 117.2M | 90.1M | 179.3M | 22.8M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 238.7M | 239.7M | 201.4M | 129.8M | 112.0M |
| Total Current Liabilities | 1.0B | 931.1M | 861.8M | 922.2M | 577.9M |
| Non-Current Liabilities | |||||
| Long-term Debt | 2.0B | 3.3B | 3.2B | 3.1B | 1.8B |
| Deferred Tax Liabilities | 403.7M | 479.7M | 617.5M | 780.6M | 236.9M |
| Other Non-Current Liabilities | 12.7M | 21.0M | 21.2M | 21.3M | 30.5M |
| Total Non-Current Liabilities | 2.5B | 3.8B | 3.9B | 4.0B | 2.1B |
| Total Liabilities | 3.5B | 4.7B | 4.7B | 4.9B | 2.7B |
| Equity | |||||
| Common Stock | 4.4B | 4.5B | 4.5B | 4.7B | 2.0B |
| Retained Earnings | 2.5B | 2.1B | 1.9B | 2.0B | 1.9B |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 6.6B | 6.3B | 6.1B | 6.5B | 3.9B |
| Key Metrics | |||||
| Total Debt | 2.2B | 3.4B | 3.2B | 3.3B | 1.8B |
| Working Capital | 978.6M | 1.9B | 1.1B | 956.8M | 633.8M |
Balance Sheet Composition
Steris plc Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 616.1M | 380.1M | 105.8M | 242.9M | 396.9M |
| Depreciation & Amortization | 476.2M | 565.2M | 552.9M | 553.1M | 219.2M |
| Stock-Based Compensation | 57.4M | 56.5M | 39.0M | 57.7M | 26.0M |
| Working Capital Changes | 27.6M | -186.0M | -228.0M | -132.9M | 9.1M |
| Operating Cash Flow | 1.1B | 908.0M | 266.3M | 687.0M | 679.7M |
| Investing Activities | |||||
| Capital Expenditures | -360.9M | -352.9M | -347.4M | -285.8M | -238.7M |
| Acquisitions | 760.4M | -536.8M | -35.9M | -380.7M | -908.7M |
| Investment Purchases | -10.8M | -1.5M | 0 | 0 | -4.4M |
| Investment Sales | 0 | 3.9M | 0 | 0 | - |
| Investing Cash Flow | 388.8M | -887.4M | -383.3M | -666.6M | -1.2B |
| Financing Activities | |||||
| Share Repurchases | -211.3M | -11.8M | -308.6M | -55.8M | -14.6M |
| Dividends Paid | -219.9M | -200.6M | -183.5M | -163.2M | -133.8M |
| Debt Issuance | - | 0 | 0 | 2.0B | 550.0M |
| Debt Repayment | -1.2B | -60.0M | -247.9M | -1.4B | -35.0M |
| Financing Cash Flow | -1.6B | -95.7M | -500.5M | 105.8M | 318.9M |
| Free Cash Flow | 778.0M | 612.9M | 395.0M | 397.2M | 450.4M |
| Net Change in Cash | -112.1M | -75.0M | -617.6M | 126.2M | -155.6M |
Cash Flow Trend
Steris plc Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
31.17
Forward P/E
20.18
Price to Book
3.06
Price to Sales
3.76
PEG Ratio
2.60
Profitability Ratios
Profit Margin
12.14%
Operating Margin
18.49%
Return on Equity
10.47%
Return on Assets
6.61%
Financial Health
Current Ratio
2.48
Debt to Equity
28.65
Beta
1.07
Per Share Data
EPS (TTM)
$7.17
Book Value per Share
$72.93
Revenue per Share
$59.30
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| STE | 21.9B | 31.17 | 3.06 | 10.47% | 12.14% | 28.65 |
| Abbott Laboratories | 160.7B | 25.97 | 3.09 | 12.36% | 13.90% | 26.79 |
| Stryker | 126.3B | 39.21 | 5.62 | 15.08% | 12.92% | 72.97 |
| Medtronic plc | 107.6B | 23.47 | 2.20 | 9.39% | 13.00% | 57.06 |
| Boston Scientific | 97.6B | 27.49 | 4.02 | 11.84% | 17.29% | 48.92 |
| Edwards Lifesciences | 48.5B | 46.49 | 4.73 | 10.38% | 17.39% | 6.82 |
Financial data is updated regularly. All figures are in the company's reporting currency.






